| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1154 | 2020 |
| Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses D Avigan, B Vasir, J Gong, V Borges, Z Wu, L Uhl, M Atkins, J Mier, ... Clinical Cancer Research 10 (14), 4699-4708, 2004 | 571 | 2004 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 436 | 2020 |
| Prospective study of fertility concerns and preservation strategies in young women with breast cancer KJ Ruddy, SI Gelber, RM Tamimi, ES Ginsburg, L Schapira, SE Come, ... Journal of Clinical Oncology 32 (11), 1151-1156, 2014 | 403 | 2014 |
| Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2 TR Lyons, J O'brien, VF Borges, MW Conklin, PJ Keely, KW Eliceiri, ... Nature medicine 17 (9), 1109-1115, 2011 | 396 | 2011 |
| Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot … HJ Burstein, LN Harris, R Gelman, SC Lester, RA Nunes, CM Kaelin, ... Journal of Clinical Oncology 21 (1), 46-53, 2003 | 371 | 2003 |
| Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species J O'Brien, T Lyons, J Monks, MS Lucia, RS Wilson, L Hines, Y Man, ... The American journal of pathology 176 (3), 1241-1255, 2010 | 314 | 2010 |
| NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and … L Fehrenbacher, RS Cecchini, CE Geyer Jr, P Rastogi, JP Costantino, ... Journal of Clinical Oncology 38 (5), 444-453, 2020 | 309 | 2020 |
| Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology PF Coccia, AS Pappo, L Beaupin, VF Borges, SC Borinstein, R Chugh, ... Journal of the National Comprehensive Cancer Network 16 (1), 66-97, 2018 | 270 | 2018 |
| Pregnancy and breast cancer: when they collide TR Lyons, PJ Schedin, VF Borges Journal of mammary gland biology and neoplasia 14, 87-98, 2009 | 268 | 2009 |
| Body image in recently diagnosed young women with early breast cancer SM Rosenberg, RM Tamimi, S Gelber, KJ Ruddy, S Kereakoglow, ... Psycho‐oncology 22 (8), 1849-1855, 2013 | 259 | 2013 |
| Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer EB Callihan, D Gao, S Jindal, TR Lyons, E Manthey, S Edgerton, ... Breast cancer research and treatment 138, 549-559, 2013 | 239 | 2013 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 235 | 2022 |
| Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium JR Palmer, E Viscidi, MA Troester, CC Hong, P Schedin, TN Bethea, ... Journal of the National Cancer Institute 106 (10), dju237, 2014 | 207 | 2014 |
| Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study R Murthy, VF Borges, A Conlin, J Chaves, M Chamberlain, T Gray, A Vo, ... The lancet oncology 19 (7), 880-888, 2018 | 192 | 2018 |
| Microenvironment of the involuting mammary gland mediates mammary cancer progression P Schedin, J O’Brien, M Rudolph, T Stein, V Borges Journal of mammary gland biology and neoplasia 12, 71-82, 2007 | 187 | 2007 |
| Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab RP Tobin, KR Jordan, WA Robinson, D Davis, VF Borges, R Gonzalez, ... International immunopharmacology 63, 282-291, 2018 | 163 | 2018 |
| Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final … G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz, S Loi, R Murthy, ... Annals of Oncology 33 (3), 321-329, 2022 | 157 | 2022 |
| Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial VF Borges, C Ferrario, N Aucoin, C Falkson, Q Khan, I Krop, S Welch, ... JAMA oncology 4 (9), 1214-1220, 2018 | 150 | 2018 |
| Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients KR Jordan, RN Amaria, O Ramirez, EB Callihan, D Gao, M Borakove, ... Cancer immunology, immunotherapy 62, 1711-1722, 2013 | 146 | 2013 |
